THE INTELLIGENT PIPELINE

In this issue

—Where AI actually stands across the full biopharma value chain

—Why biopharma moved last — and why that window has now closed

—What recent FDA and EMA signals mean for your organization, right now

—On the horizon: near-term and long-term AI possibilities by domain

From the editor

Let's be direct. When the AI wave hit biopharma — roughly 2018 to 2020 most of us in manufacturing and CMC watched from a careful distance. Discovery colleagues were publishing AlphaFold papers. Clinical teams were piloting patient stratification tools. In process development labs, we were still debating whether a PAT sensor justified its validation burden.

That caution was not irrational. It was the appropriate response of a heavily regulated industry with zero tolerance for unvalidated technology near patient-critical processes. But caution has a shelf life and ours has expired.

The regulatory goalposts have moved. The data infrastructure is maturing. The competitive pressure is real. I have worked on both sides of this downstream biologics manufacturing and AI-driven target discovery — and the conclusion from both vantage points is the same: the question is no longer whether to engage with AI. It is how to do it well, without repeating the adoption mistakes of the last decade.

This issue gives you the map.

AI adoption has not happened uniformly across the value chain. It has moved in a predictable order: fastest where regulatory stakes are lowest, slowest where GxP requirements are highest.

The pipeline below shows where each domain sits today not where vendor press releases say it sits.

Figure 1. AI maturity by domain. Number indicates relative adoption sequence. Colour encodes regulatory complexity.

Table 1. AI application maturity across the biopharma value chain. Discovery has a 5–7 year head start. Manufacturing is where the next wave of value will land.

A note on MedTech

Medical device companies — operating under lighter software validation frameworks and FDA De Novo or 510(k) pathways — have moved faster than pharma in the commercial and post-market space. Real-time patient monitoring algorithms and predictive device failure models are deployed commercially by MedTech companies that would face an 18-month GxP validation cycle for the same tool in a pharmaceutical manufacturing context.

That gap is worth watching. The learnings from MedTech's faster cycle — on model drift detection, data governance, and regulatory submission strategy for AI — are directly borrowable for pharma's next wave of deployments in pharmacovigilance and supply chain.

Every major industry adopted AI faster than biopharma. The reasons are structural and they are finally being dismantled.

Finance automated decisions in the 1990s. Retail built recommendation engines in the 2000s. Logistics ran ML-optimised routing in the 2010s. Biopharma, meanwhile, was still debating PAT sensor validation when GPT-3 was released. Two structural factors explain this and they compound each other.

The regulatory validation wall

Any software touching a GMP process requires validation under 21 CFR Part 11 and EU Annex 11. For AI tools, this means model transparency, audit trails, change control, and in high-risk applications — pre-approval agency discussions. The validation overhead for a single AI-assisted monitoring tool can run to 18–24 months in a conservative quality organisation. The ROI calculation simply did not close.

The organisational culture reinforced this. Regulatory affairs and quality teams are trained to be conservative about unvalidated technology in patient-critical processes, correctly so. But applied uniformly across all AI use cases regardless of risk profile, that conservatism created blanket slowness that went beyond rational caution.

The data quality problem is genuinely hard

Finance has millions of clean, structured transactions per day. A commercial MAb facility has 20 to 40 batches per year, generating heterogeneous data across disconnected LIMS, MES, and historian systems that were never designed to integrate. The training data problem for AI in manufacturing is real not because data does not exist, but because it exists in formats and silos that require significant data engineering before a model can touch it.

Multi-omics data in discovery is voluminous but noisy. Clinical trial data is structured for regulatory submission, not machine learning. Manufacturing process data is often locked in PDF batch records. Anyone who tells you a plug-and-play AI solution resolves this has not tried to implement one.

Table 2. AI adoption comparison across sectors. The shift from red to green in biopharma is recent — and it is accelerating.

The regulatory inflection point

FDA's 2024 AI Action Plan signals unambiguously that the agency intends to integrate AI into its own review processes and expects industry to follow. The plan specifically addresses AI use in drug development submissions, manufacturing oversight, and pharmacovigilance. EMA's 2023 reflection paper takes the same position.

Practically, FDA has signalled openness to AI-assisted submissions in:

—CMC data analysis and process understanding — directly relevant to BLA sections 3.2.P.2 and 3.2.P.3

—Patient stratification and biomarker identification in clinical sections

—Real-world evidence for post-approval commitments

—AE signal detection and case narrative processing in pharmacovigilance

This is not a future signal. The regulatory framework for AI-assisted BLA submissions exists now. Organizations still waiting for regulatory clarity before investing in AI capability are waiting for something that has already arrived.

Coming in Issue 002

Where AI in biopharma is heading — a domain-by-domain look at near-term and long-term possibilities, and what your organisation should be building toward now.